Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-22-189531
Filing Date
2022-07-07
Accepted
2022-07-07 17:00:57
Documents
1
Group Members
FLAGSHIP PIONEERING FUND VI GENERAL PARTNER LLCFLAGSHIP PIONEERING FUND VI, L.PFLAGSHIP PIONEERING FUND VII GENERAL PARTNER LLCFLAGSHIP PIONEERING FUND VII, L.P.FLAGSHIP PIONEERING, INC.FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLCFLAGSHIP VENTURES FUND I

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d331731dsc13da.htm SC 13D/A 225591
  Complete submission text file 0001193125-22-189531.txt   227727
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Subject) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88909 | Film No.: 221072219
SIC: 2834 Pharmaceutical Preparations

Mailing Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Business Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143 617-868-1888
Flagship VentureLabs IV, LLC (Filed by) CIK: 0001642578 (see all company filings)

EIN.: 461974736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A